Published in Immunology on August 28, 2008
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One (2010) 2.38
Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue. Int J Obes (Lond) (2009) 1.59
In vitro differentiation of human macrophages with enhanced antimycobacterial activity. J Clin Invest (2011) 1.29
Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv (2015) 1.25
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res (2015) 1.05
Cytokines involved in interferon-gamma production by human macrophages. J Innate Immun (2009) 1.03
Toxoplasma gondii cyclophilin 18-mediated production of nitric oxide induces Bradyzoite conversion in a CCR5-dependent manner. Infect Immun (2009) 0.96
Shared signaling systems in myeloid cell-mediated muscle regeneration. Development (2014) 0.95
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. Gene Ther (2011) 0.93
Secretion of interferon gamma from human immune cells is altered by exposure to tributyltin and dibutyltin. Environ Toxicol (2013) 0.83
Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy. Immunology (2012) 0.83
Cytokines profiling by multiplex analysis in experimental arthritis: which pathophysiological relevance for articular versus systemic mediators? Arthritis Res Ther (2012) 0.81
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother (2013) 0.80
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. Sci Rep (2016) 0.79
β-Catenin/TCF-4 signaling regulates susceptibility of macrophages and resistance of monocytes to HIV-1 productive infection. Curr HIV Res (2014) 0.79
Considerations for Defining Cytokine Dose, Duration, and Milieu That Are Appropriate for Modeling Chronic Low-Grade Inflammation in Type 2 Diabetes. J Diabetes Res (2016) 0.77
CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages. PLoS One (2016) 0.77
A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity. BMC Vet Res (2015) 0.77
A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling. Immunity (2016) 0.76
Hexabromocyclododecane and tetrabromobisphenol A alter secretion of interferon gamma (IFN-γ) from human immune cells. Arch Toxicol (2015) 0.76
Interaction of Mycoplasma gallisepticum with Chicken Tracheal Epithelial Cells Contributes to Macrophage Chemotaxis and Activation. Infect Immun (2015) 0.76
Live and inactivated Salmonella enterica serovar Typhimurium stimulate similar but distinct transcriptome profiles in bovine macrophages and dendritic cells. Vet Res (2016) 0.76
Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease. Mol Brain (2013) 0.76
Prenatal Exposure to Respiratory Syncytial Virus Alters Postnatal Immunity and Airway Smooth Muscle Contractility during Early-Life Reinfections. PLoS One (2017) 0.75
Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model. Sci Rep (2016) 0.75
Differentiated THP-1 Cells Exposed to Pathogenic and Nonpathogenic Borrelia Species Demonstrate Minimal Differences in Production of Four Inflammatory Cytokines. Vector Borne Zoonotic Dis (2016) 0.75
Gene Expression Profiling and Functional Characterization of Macrophages in Response to Circulatory Microparticles Produced during Trypanosoma cruzi Infection and Chagas Disease. J Innate Immun (2016) 0.75
Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes. Sci Rep (2017) 0.75
Tributyltin exposure alters cytokine levels in mouse serum. J Immunotoxicol (2016) 0.75
CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra low density cancer epitopes. Leukemia (2017) 0.75
Discrete dynamical modeling of influenza infection suggests age-dependent differences in immunity. J Virol (2017) 0.75
Tick-Borne Viruses and Biological Processes at the Tick-Host-Virus Interface. Front Cell Infect Microbiol (2017) 0.75
Glutamine antagonist-mediated immune suppression decreases pathology but delays virus clearance in mice during nonfatal alphavirus encephalomyelitis. Virology (2017) 0.75
Acute and neuropathic orofacial antinociceptive effect of eucalyptol. Inflammopharmacology (2017) 0.75
IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol (1999) 3.81
Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest (1985) 3.40
Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med (1998) 2.89
Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis (2003) 2.79
Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev (2000) 2.29
Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis. Infect Immun (1997) 2.16
IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol (2001) 2.13
Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med (2002) 1.91
Interleukin-12 production by human polymorphonuclear leukocytes. Eur J Immunol (1995) 1.75
Direct stimulation of macrophages by IL-12 and IL-18--a bridge too far? Immunol Lett (2000) 1.66
The production of IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. J Immunol (2001) 1.61
Production of interferon-gamma by myeloid cells--fact or fancy? Trends Immunol (2006) 1.55
IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int Immunol (2000) 1.46
Minute numbers of contaminant CD8+ T cells or CD11b+CD11c+ NK cells are the source of IFN-gamma in IL-12/IL-18-stimulated mouse macrophage populations. Blood (2004) 1.44
Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10. Clin Exp Immunol (2006) 1.05
Mycobacteria induce IFN-gamma production in human dendritic cells via triggering of TLR2. J Immunol (2006) 1.02
Activation, cytokine production, and intracellular survival of bacteria in Salmonella-infected human monocyte-derived macrophages and dendritic cells. J Leukoc Biol (2005) 0.96
Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology (2003) 0.96
Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. Vaccine (2005) 0.89
Changes in lung lymphocyte populations reflect those seen in peripheral blood in HIV-1 positive individuals. Eur Respir J (1998) 0.87
Regulation of cell-surface receptors for human interferon-gamma on the human histiocytic lymphoma cell line U937. Biochem J (1991) 0.85
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis (2006) 2.49
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS (2002) 2.29
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS (2002) 2.28
Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med (2003) 2.20
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis (2011) 2.10
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Long-term effectiveness of infrared coagulation for the treatment of anal intraepithelial neoplasia grades 2 and 3 in HIV-infected men and women. AIDS (2013) 2.06
Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol (2012) 2.03
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]. Enferm Infecc Microbiol Clin (2011) 2.03
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]. Enferm Infecc Microbiol Clin (2012) 2.02
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS (2007) 1.98
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One (2013) 1.84
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses (2008) 1.84
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr (2012) 1.84
Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med (2005) 1.83
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother (2009) 1.79
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis (2009) 1.79
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. Med Clin (Barc) (2005) 1.78
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78
High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells. J Biol Chem (2004) 1.76
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2005) 1.74
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med (2006) 1.72
The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther (2007) 1.71
Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission. J Virol (2007) 1.64
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med (2013) 1.62
Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med (2004) 1.62
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood (2008) 1.58
Global gene expression profiles in fibroblasts from synovial, skin and lymphoid tissue reveals distinct cytokine and chemokine expression patterns. Thromb Haemost (2003) 1.55
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr (2012) 1.53
Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. Blood (2008) 1.53
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 1.52
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS (2007) 1.51
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One (2012) 1.48
Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS (2011) 1.45
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med (2003) 1.44
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J (2002) 1.42
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm Infecc Microbiol Clin (2004) 1.42
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther (2011) 1.41
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. J Infect (2011) 1.39
[Usefulness of a lung cancer rapid diagnosis specialist clinic. Contribution of ultrasound bronchoscopy]. Arch Bronconeumol (2010) 1.39
Drug resistance mutations in HIV-1. Top HIV Med (2004) 1.37
Virological rebound after suppression on highly active antiretroviral therapy. AIDS (2003) 1.34
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One (2010) 1.33
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artif Intell Med (2009) 1.31
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS (2010) 1.30
CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS (2010) 1.30
A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission. Antiviral Res (2008) 1.30
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology (2013) 1.30
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Antivir Ther (2008) 1.29
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS (2002) 1.28
Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis (2010) 1.27